ImpriMed Raises $35M to Expand AI for Personalized Cancer Treatment from Dogs to Humans
-
ImpriMed builds AI tech for personalized dog cancer treatment to help vets identify best drugs for individual canine/feline blood cancers
-
The startup now aims to expand its precision medicine tech into human oncology applications in 1-2 years
-
ImpriMed raised $23M in Series A funding, bringing total raised to $35M, to partner with SK Telecom and validate models using Mayo Clinic data
-
Its veterinary cancer services are commercialized, used by 350+ vets in U.S.; human multiple myeloma AI pending 2025 approval
-
The startup helped over 5,000 dogs with lymphoma, boosting complete response rates and survival times by using personalized treatment predictions